lindor keith (36 Ergebnisse)

Hardcover. Zustand: Very Good. No Jacket. May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend Less.

Zustand: Very Good. Used book that is in excellent condition. May show signs of wear or have minor defects.

Zustand: New. pp. 206 52:B&W 6.14 x 9.21in or 234 x 156mm (Royal 8vo) Case Laminate on White w/Gloss Lam.

Paperback. Zustand: Good. No Jacket. Pages can have notes/highlighting. Spine may show signs of wear. ~ ThriftBooks: Read More, Spend Less.

hardcover. Zustand: Very Good. Zustand des Schutzumschlags: No Dust Jacket. Excellent, clean, unmarked condition. Stamp on back inside cover. Tiny dent on back cover.

Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

2nd ed. 2014. x, 259 p. Hardcover. Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, daher Mängelexemplar gestempelt, sonst sehr guter Zustand. Imperfect copy due to slightly bumped cover, apart from this in very good condition. Stamped. Stamped.

Cloth/Laminated Boards. Zustand: Very Good. Type: Book The proceedings of a one-day symposium held in Chicago, USA, on November 6, 1997, provide an update for hepatologists, gastroenterologists, and basic scientists with an interest in primary biliary cirrhosis. New insights into the pathogenesis and the natural history of the disease are discussed, and approaches to management of the complications as well as newer therapeutic options are presented.192pp.Slight marking at the base of the spine.

Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Hardcover. Zustand: Very Good. No Jacket. May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend Less.

Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Zustand: New. Packed with Board-focused hints, case studies and 250 Board-standard test MCQs, Gastroenterology and Hepatology Board Review Toolkit is the ideal toolkit for gastroenterology residents and fellows to consult throughout their training, particularly those pre.

Zustand: New. pp. 424.

Paperback. Zustand: Brand New. 2nd edition. 658 pages. 11.50x9.00x1.00 inches. In Stock.

Zustand: New. Cholestatic Liver Disease Editor(s): Carey, Elizabeth J.; Lindor, Keith D. Series: Clinical Gastroenterology. Num Pages: 269 pages, 14 black & white illustrations, 20 colour illustrations, 34 black & white tables, biograp. BIC Classification: MBPC; MJH; MN. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 16. Weight in Grams: 573. . 2014. 2nd ed. 2014. Hardcover. . . . . Books ship from the US and Ireland.

Buch. Zustand: Neu. Neuware -Since the publication of the first edition, there have been advances in both the diagnosis and the management of many of the cholestatic liver diseases. Cholestatic Liver Disease, Second Edition thoroughly updates the topics previously addressed, such as primary biliary cirrhosis, primary sclerosing cholangitis and cholestatic variants of drug hepatotoxicity and viral disease. New treatments, such as the development of the farnesoid X receptor agonists for the treatment of PBC, are highlighted. Current guidelines and areas of uncertainty are also covered. Additionally, new chapters have been added to reflect the changing landscape of cholestatic liver disease.Cholestatic Liver Disease, Second Edition is a concise yet comprehensive summary of the current status of the field and is of value to clinicians and researchers interested in patients with cholestatic liver disease provide that will help to guide patient management and stimulate investigative efforts.Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin 272 pp. Englisch.

Taschenbuch. Zustand: Neu. Neuware - Packed with Board-focused hints, case studies and an online Board-standard MCQ test offering CME credits, this fantastic book covers every gastroenterology disease and symptom you're likely to encounter and is the perfect tool to prepare for Board exams and certification.

Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Since the publication of the first edition, there have been advances in both the diagnosis and the management of many of the cholestatic liver diseases. Cholestatic Liver Disease, Second Edition thoroughly updates the topics previously addressed, such as primary biliary cirrhosis, primary sclerosing cholangitis and cholestatic variants of drug hepatotoxicity and viral disease. New treatments, such as the development of the farnesoid X receptor agonists for the treatment of PBC, are highlighted. Current guidelines and areas of uncertainty are also covered. Additionally, new chapters have been added to reflect the changing landscape of cholestatic liver disease.Cholestatic Liver Disease, Second Edition is a concise yet comprehensive summary of the current status of the field and is of value to clinicians and researchers interested in patients with cholestatic liver disease provide that will help to guide patient management and stimulate investigative efforts.

Taschenbuch. Zustand: Neu. Cholestatic Liver Disease | Elizabeth J. Carey (u. a.) | Taschenbuch | x | Englisch | 2016 | Humana | EAN 9781493938926 | Verantwortliche Person für die EU: Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

Paperback. Zustand: Brand New. 2nd reprint edition. 269 pages. 9.25x6.10x0.64 inches. In Stock.

Taschenbuch. Zustand: Neu. Neuware -Since the publication of the first edition, there have been advances in both the diagnosis and the management of many of the cholestatic liver diseases. Cholestatic Liver Disease, Second Edition thoroughly updates the topics previously addressed, such as primary biliary cirrhosis, primary sclerosing cholangitis and cholestatic variants of drug hepatotoxicity and viral disease. New treatments, such as the development of the farnesoid X receptor agonists for the treatment of PBC, are highlighted. Current guidelines and areas of uncertainty are also covered. Additionally, new chapters have been added to reflect the changing landscape of cholestatic liver disease.Cholestatic Liver Disease, Second Edition is a concise yet comprehensive summary of the current status of the field and is of value to clinicians and researchers interested in patients with cholestatic liver disease provide that will help to guide patient management and stimulate investigative efforts.Humana Press in Springer Science + Business Media, Heidelberger Platz 3, 14197 Berlin 272 pp. Englisch.

Gebunden. Zustand: New. Editor-in-Chief:Nicholas J. Talley, MD, PhD, Chair, Department of Internal Medicine, Mayo Clinic College of Medicine, Jacksonville, Florida, USAAssociate editors:Keith D. Lindor, MD, Professor of Medicine, Division of Gastroenterology and Hepatology, Mayo C.

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Since the publication of the first edition, there have been advances in both the diagnosis and the management of many of the cholestatic liver diseases. Cholestatic Liver Disease, Second Edition thoroughly updates the topics previously addressed, such as primary biliary cirrhosis, primary sclerosing cholangitis and cholestatic variants of drug hepatotoxicity and viral disease. New treatments, such as the development of the farnesoid X receptor agonists for the treatment of PBC, are highlighted. Current guidelines and areas of uncertainty are also covered. Additionally, new chapters have been added to reflect the changing landscape of cholestatic liver disease.Cholestatic Liver Disease, Second Edition is a concise yet comprehensive summary of the current status of the field and is of value to clinicians and researchers interested in patients with cholestatic liver disease provide that will help to guide patient management and stimulate investigative efforts.

Zustand: New. pp. 188 52:B&W 6.14 x 9.21in or 234 x 156mm (Royal 8vo) Case Laminate on White w/Gloss Lam.

Zustand: New. Editor(s): Carey, Elizabeth J.; Lindor, Keith D. Series: Clinical Gastroenterology. Num Pages: 269 pages, 14 black & white illustrations, 20 colour illustrations, 34 black & white tables, biograp. BIC Classification: MJJ. Category: (P) Professional & Vocational. Dimension: 235 x 155 x 14. Weight in Grams: 421. . 2016. Softcover reprint of the original 2nd ed. 2014. paperback. . . . . Books ship from the US and Ireland.

Zustand: New. In this volume devoted to the liver and biliary diseases, a group of global experts provide essential information for Board preparation and background reading. Each focuses on one key topic, with the most important clinical facts highlighted in boxes. Color illustrations reinforce the text. Num Pages: 424 pages, col. ill. BIC Classification: MJH; MJJ. Category: (P) Professional & Vocational. Dimension: 255 x 199 x 27. Weight in Grams: 1174. . 2010. . . . . Books ship from the US and Ireland.

Taschenbuch. Zustand: Neu. Primary Biliary Cirrhosis | From Pathogenesis to Clinical Treatment | Keith D. Lindor (u. a.) | Taschenbuch | xv | Englisch | 2012 | Springer | EAN 9789401060479 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

Buch. Zustand: Neu. Neuware -The condition of prolonged obstructive jaundice with patent bile ducts was first described in 1851 by Addison and Gull of Guy's Hospital, London. The term primary biliary cirrhosis (PBC) was defined in 1950 by Ahrens and colleagues of the Rockefeller Institute, New York. The condition was considered rare but this changed in 1965 with the discovery of a definitive diagnostic serum mitochondrial antibody test and the recognition that a raised serum alkaline phosphatase value, often discovered incidentally, could be a diagnostic pointer. If the diagnosis is made earlier, the end stages are rarely reached as death is replaced by liver transplantation. On November 6th 1997, in Chicago, an International Faculty discussed in depth the clinical features, pathogenesis and treatment of PBC, no longer considered a rare disease. The course of PBC is long, but some 18 years after the discovery of a positive mitochondrial antibody test in a symptom free patient with normal serum biochemistry, 83% will have developed abnormal tests and 76% will be symptomatic. Identification of those who will progress rapidly is difficult. The serum antimitochondrial profile may be useful but this is a very specialist technique. Mathematical prognostic models are useful in therapeutic trials and in the selection and timing of patients for liver transplantation but have limited value in individual patients. An increasing serum bilirubin level remains the most important indicator of rapid progression. Its value however can be negated by the use of ursodeoxycholic acid which has a bilirubin-lowering effect.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 188 pp. Englisch.

Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - The condition of prolonged obstructive jaundice with patent bile ducts was first described in 1851 by Addison and Gull of Guy's Hospital, London. The term primary biliary cirrhosis (PBC) was defined in 1950 by Ahrens and colleagues of the Rockefeller Institute, New York. The condition was considered rare but this changed in 1965 with the discovery of a definitive diagnostic serum mitochondrial antibody test and the recognition that a raised serum alkaline phosphatase value, often discovered incidentally, could be a diagnostic pointer. If the diagnosis is made earlier, the end stages are rarely reached as death is replaced by liver transplantation. On November 6th 1997, in Chicago, an International Faculty discussed in depth the clinical features, pathogenesis and treatment of PBC, no longer considered a rare disease. The course of PBC is long, but some 18 years after the discovery of a positive mitochondrial antibody test in a symptom free patient with normal serum biochemistry, 83% will have developed abnormal tests and 76% will be symptomatic. Identification of those who will progress rapidly is difficult. The serum antimitochondrial profile may be useful but this is a very specialist technique. Mathematical prognostic models are useful in therapeutic trials and in the selection and timing of patients for liver transplantation but have limited value in individual patients. An increasing serum bilirubin level remains the most important indicator of rapid progression. Its value however can be negated by the use of ursodeoxycholic acid which has a bilirubin-lowering effect.